Table 3.
Summary of cumulative incidence of acute and chronic GvHD.
| aGvHD | Treosulfan (N = 65) |
|---|---|
| Grades I–IV | |
| Subjects with event [n (%)] | 29 (44.6%) |
| Cumulative incidence of acute GvHD at 100 days (%) | 45.3 |
| 90% CI | (35.1, 55.5) |
| Grades II–IV | |
| Subjects with event [n (%)] | 17 (26.2%) |
| Cumulative incidence of acute GvHD at 100 days (%) | 26.6 |
| 90% CI | (17.5, 35.6) |
| Grades III–IV | |
| Subjects with event [n (%)] | 5 (7.7%) |
| Cumulative incidence of acute GvHD at 100 days (%) | 7.8 |
| 90% CI | (2.3, 13.3) |
| Overall | |
| Subjects with event [n (%)] | 16 (25.8%) |
| Cumulative incidence of cGvHD at 36 months (%) | 25.8 |
| 90% CI | (16.7, 34.9) |
| Moderate/severe | |
| Subjects with event [n (%)] | 12 (19.4%) |
| Cumulative incidence of cGvHD at 36 months (%) | 19.4 |
| 90% CI | (11.1, 27.7) |
CI confidence interval, aGvHD acute graft-vs.-host disease, cGvHD chronic graft-vs.-host disease, N number of subjects, n number of subjects in category.